Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-hexosaminidase subunit alpha, also known as Hex A, is the α-subunit of the lysosomal enzyme β-hexosaminidase A, an αβ heterodimer encoded by the HEXA gene, essential for hydrolyzing terminal N-acetyl-D-hexosamine residues, particularly from GM2 gangliosides in the nervous system with the aid of GM2 activator protein. The α-subunit's active site, featuring a flexible loop (Gly280-Pro283) and key residues like αArg424, enables specific GM2 degradation, unlike the β-subunit which handles neutral substrates. Defects in HEXA cause Tay-Sachs disease, a fatal lysosomal storage disorder from GM2 accumulation in neurons, leading to neurodegeneration. Mutant α-chains often misfold, fail to dimerize with β, and undergo ERAD, preventing lysosomal trafficking. Therapeutic strategies include pharmacological chaperones like NGT, which stabilize the native α-conformation to enhance folding, dimerization, and activity for late-onset variants. The enzyme's TIM barrel active sites use a substrate-assisted mechanism with Glu323 as acid-base and Asp322 stabilizing the oxazolinium intermediate. Crystal structures confirm dimerization's role in stability and dual active sites. Targeting Hex A holds promise for GM2 gangliosidoses but faces challenges from ER quality control and residual activity needs.
Pharmacological chaperone stabilizing α-subunit conformation to promote dimerization, ER exit, and lysosomal targeting; Substrate-assisted catalysis via glutamate acid-base and aspartate stabilization of oxazolinium intermediate for GalNAc/GlcNAc cleavage
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-hexosaminidase subunit alpha (Hex A) (Hex A).